文献速递真菌感染

尿MycoMEIA曲霉检测辅助诊断侵袭性曲霉病的性能

Performance of the Urinary MycoMEIA Aspergillus Assay as an Aid to Diagnose Invasive Aspergillosis.
PubMed 文献 · Clin Infect Dis · 2026-10-07

该研究评估尿MycoMEIA曲霉检测辅助诊断侵袭性曲霉病(IA)的性能,采用病例对照和前瞻性队列设计,共检测469份尿液样本(50例IA病例和240例对照)。结果显示敏感度92%、特异度87.6%,前瞻性队列特异度89.7%,可提前5天阳性,部分与其他子囊菌真菌交叉反应。

要点

  • 尿MycoMEIA检测敏感度92%、特异度87.6%,可用于辅助诊断IA。
  • 对血清GM EIA阴性但BAL诊断的IA病例,尿检可检出79.2%。
  • 前瞻性队列中特异度89.7%,可提前5天阳性。

核心结论

  • MycoMEIA作为辅助诊断IA的手段表现良好,高敏感度和阴性预测值可能有助于减少不必要的经验性抗真菌治疗。

研究设计与样本

  • 采用病例对照研究和前瞻性队列研究评估MycoMEIA辅助诊断IA的性能。
  • 共检测469份尿液样本,来自50例IA病例和240例对照。

主要发现

  • MycoMEIA敏感度为92%(95% CI 80.8-97.8),特异度为87.6%(95% CI 82.8-91.8)。
  • 所有血清GM EIA阳性的IA病例,MycoMEIA均为阳性。
  • 尿检检出19/24(79.2%)经BAL诊断但血清GM EIA阴性的IA病例。
  • 尿检阳性较临床诊断提前5天(范围-21至+14天)。
  • 前瞻性检测确认特异度为89.7%(95% CI 75.8-97.1),在102例疑似「可能IA」患者中检出28例(27.5%)IA。

关键数值与推荐

  • 以「确诊」或「临床诊断」IA的共识标准及对照评估性能。
  • 额外分析评估「可能IA」中的阳性率、与血清GM EIA的一致性、交叉反应及阳性时间。
  • 三个实验室间评估重现性。

临床怎么用

  • 尿MycoMEIA可作为辅助诊断IA的无创检测,尤其适用于无法获取侵入性标本的患者。
  • 高阴性预测值可能帮助减少不必要的经验性抗真菌治疗。
  • 需进一步研究明确其在筛查和更广泛患者群体中的作用。

局限性

  • 观察到与其他子囊菌真菌存在一定交叉反应。
  • 需进一步研究定义其在筛查和更广泛患者群体中的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive aspergillosis (IA) is difficult to diagnose, contributing to poor clinical outcomes and unnecessary antifungal therapies. The MycoMEIA Aspergillus assay (MycoMEIA), which detects Aspergillus glycans in urine, does not require invasive specimens. We report data that supported regulatory approval. METHODS: A case-control study and prospective cohort study were conducted to evaluate MycoMEIA as an aid to diagnose IA. Performance was assessed using consensus criteria of "proven" or "probable" IA and controls. Additional analyses evaluated positivity in "possible" IA, agreement with serum galactomannan (GM EIA), cross-reactivity, and timing of positivity relative to clinical diagnosis. Reproducibility was assessed across three laboratories. RESULTS: In brief, 469 urine samples from 50 IA cases and 240 controls demonstrated MycoMEIA 92% (95% CI 80.8-97.8) sensitivity and 87.6% (95% CI 82.8-91.8) specificity. All cases with positive serum GM EIA were positive by MycoMEIA. Urine testing identified 19/24 (79.2%) IA cases diagnosed by bronchoalveolar lavage (BAL) but negative by serum GM EIA and provided lead-time positivity of 5 days (range -21 to +14) before clinical diagnosis. Prospective testing confirmed a specificity of 89.7% (95% CI 75.8-97.1) and identified IA in 28/102 (27.5%) people with suspected "possible" IA. Some cross-reactivity was observed with other Ascomycetes fungi. Results were reproducible across sites. CONCLUSIONS: MycoMEIA shows strong performance as an aid to diagnose IA. Its high sensitivity and negative predictive value may help reduce unnecessary empirical antifungals. Further studies are needed to define its role in screening and broader patient populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Baburina I, Marr KA, Vanbiervliet Y, et al. Performance of the Urinary MycoMEIA Aspergillus Assay as an Aid to Diagnose Invasive Aspergillosis. Clin Infect Dis. 2026. PMID: 42841776. doi:10.1093/cid/ciag522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。